Company news

Oncolytics Biotech Inc. news in 2024

Oncolytics Biotech Inc.'s news releases, calls and decks from 2024, newest first.

View company

Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

December 2, 2024

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights

November 11, 2024

Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path

October 3, 2024

Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study

September 18, 2024

Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights

July 31, 2024

Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program

June 26, 2024

Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence

June 23, 2024

Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer

June 19, 2024

Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action

May 23, 2024

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 14, 2024

Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights

May 8, 2024

Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

April 25, 2024

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

April 11, 2024

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

March 6, 2024

Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning

March 6, 2024

Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN

March 4, 2024

Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments

February 15, 2024

Oncolytics Biotech® Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort

February 13, 2024

Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors

January 9, 2024

Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

January 3, 2024

Calls in 2024

Decks in 2024